CU20160039A7 - PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE - Google Patents

PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE

Info

Publication number
CU20160039A7
CU20160039A7 CUP2016000039A CU20160039A CU20160039A7 CU 20160039 A7 CU20160039 A7 CU 20160039A7 CU P2016000039 A CUP2016000039 A CU P2016000039A CU 20160039 A CU20160039 A CU 20160039A CU 20160039 A7 CU20160039 A7 CU 20160039A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
compositions containing
derivatives
benzotiofen
pirrolo
Prior art date
Application number
CUP2016000039A
Other languages
English (en)
Other versions
CU24426B1 (es
Inventor
Dirk Brohm
Melanie Heroult
Marie-Pierre Collin
Walter Hübsch
Mario Lobell
Klemens Lustig
Sylvia Grünewald
Ulf Bömer
Verena VÖHRINGER
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of CU20160039A7 publication Critical patent/CU20160039A7/es
Publication of CU24426B1 publication Critical patent/CU24426B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se refiere a procedimientos de preparación de derivados de 5-(1-benzotiofen-2-il)pirrolo[2,1-f][1,2,4] -driazin-4-amina que tienen actividades inhibidoras de la proteína tirosina quinasa y composiciones farmacéuticas que contienen estos compuestos, para tratar trastornos proliferativos, en particular, cáncer y enfermedades tumorales.
CU2016000039A 2011-12-15 2012-12-10 PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE CU24426B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11193841 2011-12-15
PCT/EP2012/074977 WO2013087578A1 (en) 2011-12-15 2012-12-10 Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors

Publications (2)

Publication Number Publication Date
CU20160039A7 true CU20160039A7 (es) 2016-08-31
CU24426B1 CU24426B1 (es) 2019-06-04

Family

ID=47326168

Family Applications (2)

Application Number Title Priority Date Filing Date
CU2016000039A CU24426B1 (es) 2011-12-15 2012-12-10 PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE
CUP2014000065A CU20140065A7 (es) 2011-12-15 2014-06-09 DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL) PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA

Family Applications After (1)

Application Number Title Priority Date Filing Date
CUP2014000065A CU20140065A7 (es) 2011-12-15 2014-06-09 DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL) PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA

Country Status (42)

Country Link
US (4) US20140336173A1 (es)
EP (1) EP2791140B1 (es)
JP (1) JP6050829B2 (es)
KR (1) KR102057444B1 (es)
CN (1) CN104245700B (es)
AR (1) AR089207A1 (es)
AU (3) AU2012350750B2 (es)
BR (1) BR112014014531B1 (es)
CA (1) CA2859133C (es)
CL (1) CL2014001547A1 (es)
CO (1) CO7030961A2 (es)
CR (1) CR20140288A (es)
CU (2) CU24426B1 (es)
CY (1) CY1118112T1 (es)
DK (1) DK2791140T3 (es)
DO (1) DOP2014000127A (es)
EA (1) EA029556B1 (es)
EC (1) ECSP14004722A (es)
ES (1) ES2591203T3 (es)
GT (1) GT201400113A (es)
HR (1) HRP20161130T1 (es)
HU (1) HUE029582T2 (es)
IL (1) IL232611A (es)
IN (1) IN2014CN04310A (es)
JO (1) JO3295B1 (es)
LT (1) LT2791140T (es)
ME (1) ME02517B (es)
MX (1) MX367158B (es)
MY (1) MY178660A (es)
PE (1) PE20141855A1 (es)
PH (1) PH12014501355A1 (es)
PL (1) PL2791140T3 (es)
PT (1) PT2791140T (es)
RS (1) RS55144B1 (es)
SG (1) SG11201402325QA (es)
SI (1) SI2791140T1 (es)
TN (1) TN2014000255A1 (es)
TW (1) TWI567076B (es)
UA (1) UA116768C2 (es)
UY (1) UY34484A (es)
WO (1) WO2013087578A1 (es)
ZA (1) ZA201405140B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10388493B2 (en) 2011-09-16 2019-08-20 Lam Research Corporation Component of a substrate support assembly producing localized magnetic fields
UY34484A (es) * 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
TR201907147T4 (tr) 2013-07-18 2019-06-21 Taiho Pharmaceutical Co Ltd Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
US9212178B2 (en) * 2013-10-21 2015-12-15 Genosco Substituted pyrimidine compounds and their use as SYK inhibitors
EP3229800A2 (en) * 2014-12-11 2017-10-18 Bayer Pharma Aktiengesellschaft Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor
KR20180013851A (ko) * 2015-03-09 2018-02-07 바이엘 파마 악티엔게젤샤프트 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP7085985B2 (ja) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
IL293496B2 (en) 2016-03-28 2023-05-01 Incyte Corp Pyrrolotriazine compounds as TAM inhibitors
CN107513068A (zh) * 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
AU2017378324B2 (en) 2016-12-16 2021-09-02 Cystic Fibrosis Foundation Bycyclic heteroaryl derivatives as CFTR potentiators
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
KR102707041B1 (ko) * 2017-08-15 2024-09-19 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Fgfr 억제제 및 그의 의학적 용도
WO2019034075A1 (zh) * 2017-08-15 2019-02-21 南京明德新药研发股份有限公司 Fgfr和egfr抑制剂
MA50655B1 (fr) 2017-09-27 2021-11-30 Incyte Corp Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
MX2020004285A (es) * 2017-10-25 2020-07-29 Bayer Pharma AG Proceso para preparar el benzotiofen-2-il boronato.
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
AU2019293618B2 (en) 2018-06-29 2025-04-17 Incyte Corporation Formulations of an AXL/MER inhibitor
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
EP3917929A1 (en) * 2019-01-31 2021-12-08 Bayer Aktiengesellschaft The monohydrate of rogaratinib hydrochloride and solid states thereof
JP7355834B2 (ja) * 2019-02-15 2023-10-03 石薬集団中奇制薬技術（石家庄）有限公司 固体形態のｆｇｆｒ阻害剤化合物およびその製造方法
WO2020170355A1 (ja) * 2019-02-20 2020-08-27 大鵬薬品工業株式会社 Ｆｇｆｒ１変異腫瘍の治療方法
CN109928976A (zh) * 2019-02-26 2019-06-25 泰州亿腾景昂药业有限公司 一种工业化生产eoc317的方法
TWI857043B (zh) 2019-04-12 2024-10-01 美商纜圖藥品公司 用於治療ｋｉｔ及ｐｄｇｆｒａ介導之疾病的組合物及方法
CA3137458A1 (en) 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
WO2021089005A1 (zh) * 2019-11-08 2021-05-14 石药集团中奇制药技术（石家庄）有限公司 一种fgfr抑制剂的用途
CN111004234A (zh) * 2019-11-28 2020-04-14 湖南农业大学 一种2-苯基咪唑并[1,2-α]吡啶类化合物的C3位卤化方法
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CN117402161A (zh) * 2022-07-06 2024-01-16 上海科恩泰生物医药科技有限公司 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
EP4704850A1 (en) 2023-05-04 2026-03-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1183033T3 (da) * 1999-05-21 2006-06-06 Bristol Myers Squibb Co Pyrrolotriazininhibitorer af kinaser
CN1390220A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
WO2004096806A1 (ja) * 2003-04-30 2004-11-11 Sumitomo Pharmaceuticals Co. Ltd. 縮合イミダゾール誘導体
DE10327439A1 (de) * 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
AU2005230818B2 (en) 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
ES2436877T3 (es) * 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
WO2007064932A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc. Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
WO2007064931A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW201307354A (zh) * 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
UY34484A (es) * 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos

Also Published As

Publication number Publication date
PE20141855A1 (es) 2014-11-26
KR20140103328A (ko) 2014-08-26
SI2791140T1 (sl) 2016-10-28
PH12014501355B1 (en) 2014-09-22
AR089207A1 (es) 2014-08-06
CN104245700A (zh) 2014-12-24
US20190016724A1 (en) 2019-01-17
US20220153745A1 (en) 2022-05-19
HRP20161130T1 (hr) 2016-11-18
IL232611A0 (en) 2014-06-30
PL2791140T3 (pl) 2017-08-31
CA2859133A1 (en) 2013-06-20
UY34484A (es) 2013-07-31
EA029556B1 (ru) 2018-04-30
CU20140065A7 (es) 2014-11-27
DOP2014000127A (es) 2014-08-15
CO7030961A2 (es) 2014-08-21
PT2791140T (pt) 2016-09-20
HK1205123A1 (en) 2015-12-11
TN2014000255A1 (en) 2015-09-30
HUE029582T2 (en) 2017-03-28
CN104245700B (zh) 2016-11-16
SG11201402325QA (en) 2014-09-26
MX367158B (es) 2019-08-07
JP2015500307A (ja) 2015-01-05
PH12014501355A1 (en) 2014-09-22
EP2791140A1 (en) 2014-10-22
GT201400113A (es) 2015-08-25
UA116768C2 (uk) 2018-05-10
EA201400707A1 (ru) 2014-11-28
TWI567076B (zh) 2017-01-21
AU2012350750A1 (en) 2014-06-12
US20130158000A1 (en) 2013-06-20
ES2591203T3 (es) 2016-11-25
WO2013087578A1 (en) 2013-06-20
JO3295B1 (ar) 2018-09-16
BR112014014531B1 (pt) 2022-02-08
KR102057444B1 (ko) 2019-12-19
RS55144B1 (sr) 2016-12-30
CR20140288A (es) 2014-07-14
CL2014001547A1 (es) 2014-10-24
US20140336173A1 (en) 2014-11-13
NZ625073A (en) 2016-07-29
ECSP14004722A (es) 2015-11-30
BR112014014531A2 (pt) 2019-08-06
CU24426B1 (es) 2019-06-04
CA2859133C (en) 2020-03-24
EP2791140B1 (en) 2016-06-15
ZA201405140B (en) 2017-04-26
US9206184B2 (en) 2015-12-08
TW201339162A (zh) 2013-10-01
AU2017206140A1 (en) 2017-08-03
LT2791140T (lt) 2016-10-10
ME02517B (me) 2017-02-20
MY178660A (en) 2020-10-20
AU2012350750B2 (en) 2017-08-03
MX2014006905A (es) 2014-09-08
CY1118112T1 (el) 2017-06-28
IL232611A (en) 2017-05-29
JP6050829B2 (ja) 2016-12-21
DK2791140T3 (en) 2016-09-19
AU2019204255A1 (en) 2019-07-04
IN2014CN04310A (es) 2015-09-04

Similar Documents

Publication Publication Date Title
CU20160039A7 (es) PROCEDIMIENTO DE PREPARACIÓN DE DERIVADOS DE 5-(1-BENZOTIOFEN-2-IL)PIRROLO[2,1-f][1,2,4]TRIAZIN-4-AMINA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENE
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
EA201391682A1 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
BR112015002152A2 (pt) pirróis substituídos ativos como inibidores de quinases
MX2017006366A (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
HK1203927A1 (en) Heterocyclic compounds and uses as anticancer agents
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
EA201790267A1 (ru) Новые модуляторы киназ
CL2014001103A1 (es) Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
EA201390520A1 (ru) Замещенные соединения пиридазинкарбоксамида
MX2012000166A (es) Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos.
CL2012003637A1 (es) Compuestos derivados de quinazolina o triazolopiridina sustituidos, inhibidores selectivos de tirosina quinasa; medicamento; composicion farmaceutica; y su uso para tratar, prevenir o mejorar edema retiniano/macular, degeneración macular relacionada con la edad y derrame vascular retiniano relacionado con isquemia, entre otras.
EA201692255A1 (ru) Улучшенные формы селективного ингибитора pi3k-дельта для применения в фармацевтических препаратах
EA201390519A1 (ru) Замещенные соединения пиридазинкарбоксамида в качестве киназных ингибиторов
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa
EA201690655A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA202092370A1 (ru) Новые модуляторы киназ